The Expression of SPARC in Human Intracranial Aneurysms and Its Relationship with MMP-2/-9

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Li, Bo ^a   Li, Feng ^a   Chi, Lingyi ^a   Zhang, Liangwen ^a   Zhu, Shugan ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; OSTEONECTIN;

ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACRANIAL ANEURYSM; MALE; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SYNDROME DELINEATION; UPREGULATION; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; ANEURYSM, RUPTURED; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INTRACRANIAL ANEURYSM; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84875030914     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058490     Document Type: Article

References (59)

1. Grond-Ginsbach C, Schnippering H, Hausser I, (2002) Ultrastructural connective tissue aberrations in patients with intracranial aneurysms. Stroke 33: 2192-2196.
2. Juvela S, Hillbom M, Numminen H, Koskinen P, (1993) Cigarette smoking and alcohol consumption as risk factors for aneurysmal subarachnoid hemorrhage. Stroke 24: 639-646.
3. Juvela S, (2003) Prehemorrhage risk factors for fatal intracranial aneurysm rupture. Stroke 34: 1852-1858.
4. Kataoka K, Taneda M, Asai T, Kinoshita A, Ito M, et al. (1999) Structural fragility and inflammatory response of ruptured cerebral aneurysms. A comparative study between ruptured and unruptured cerebral aneurysms. Stroke 30: 1396-1401.
5. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, et al. (1981) Osteonectin,a bone-specific protein linking mineral to collagen. Cell 26: 99-105.
6. Lane TF, Saga FH, (1994) The biology of SPARC, a protein that modulates cell-matrix interaction. FASEB J 8: 163-173.
7. Hirota S, Imakita M, Kohri K, Ito A, Morii E, et al. (1993) Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. Am J Pathol 143: 1003-1008.
8. Rivera LB, Bradshaw AD, Brekken RA, (2011) The regulatory function of SPARC in vascular biology. Cell Mol Life Sci 68: 3165-3173.
9. Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, et al. (2008) The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 27: 691-705.
10. Chlenski A, Guerrero LJ, Peddinti R, Spitz JA, Leonhardt PT, et al. (2010) Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors. Mol Cancer 9: 138.
11. Porter PL, Sage EH, Lane TF, Funk SE, Gown AM, (1995) Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 43: 791-800.
12. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL, (2000) Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 6: 1140-1149.
13. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, et al. (1997) The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 108: 210-214.
14. Rempel SA, Golembieski WA, Ge S, Lemke N, Elisevich K, et al. (1998) SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. J Neuropathol Exp Neurol 57: 1112-1121.
15. Porte H, Triboulet JP, Kotelevets L, Carrat F, Prévot S, et al. (1998) Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. Clin Cancer Res 4: 1375-1382.
16. Koukourakis MI, Giatromanolaki A, Brekken RA, Sivridis E, Gatter KC, et al. (2003) Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 63: 5376-5380.
17. Nishie A, Masuda K, Otsubo M, Migita T, Tsuneyoshi M, et al. (2001) High expression of the Cap43 gene in infiltrating macrophages of human renal cell carcinomas. Clin Cancer Res 7: 2145-2151.
18. Yamanaka M, Kanda K, Li NC, Fukumori T, Oka N, et al. (2001) Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol 166: 2495-2499.
19. Le Bail B, Faouzi S, Boussarie L, Guirouilh J, Blanc JF, et al. (1999) Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. J Pathol 189: 46-52.
20. Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, et al. (2001) SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 159: 609-622.
21. Yang E, Kang HJ, Koh KH, Rhee H, Kim NK, et al. (2007) Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer 121: 567-575.
22. Puolakkainen PA, Brekken RA, Muneer S, Sage EH, (2004) Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res 2: 215-224.
23. Chen G, Tian X, Liu Z, Zhou S, Schmidt B, et al. (2010) Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression. Br J Cancer 102: 188-195.
24. DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, et al. (2006) Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia 20: 426-432.
25. Gilles C, Bassuk JA, Pulyaeva H, Sage EH, Foidart JM, et al. (1998) SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res 58: 5529-5536.
26. Porte H, Triboulet JP, Kotelevets L, Carrat F, Prévot S, et al. (1998) Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. Clin Cancer Res 4: 1375-1382.
27. Folkman J, (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
28. Brekken RA, Sage EH, (2001) SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 19: 816-827.
29. Cen L, Liu W, Cui L, Zhang W, Cao Y, (2008) Collagen tissue engineering: development of novel biomaterials and applications. Pediatr Res 63: 492-496.
30. Malemud CJ, (2006) Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11: 1696-1701.
31. Yong VW, Power C, Forsyth P, Edwards DR, (2001) Matrix metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2: 502-511.
32. Montaner J, Alvarez-Sabín J, Molina C, Anglés A, Abilleira S, et al. (2001) Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 32: 1759-1766.
33. D'Armiento FP, Bianchi A, de Nigris F, Capuzzi DM, D'Armiento MR, et al. (2001) Age-related effects on atherogenesis and scavenger enzymes of intracranial and extracranial arteries in men without classical risk factors for atherosclerosis. Stroke 32: 2472-2479.
34. Napoli C, Palinski W, (2005) Neurodegenerative diseases: insights into pathogenic mechanisms from atherosclerosis. Neurobiol Aging 26: 293-302.
35. Bhoopathi P, Chetty C, Gujrati M, Dinh DH, Rao JS, et al. (2010) The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine. Br J Cancer 102: 530-540.
36. Caird J, Napoli C, Taggart C, Farrell M, Bouchier-Hayes D, (2006) Matrix metalloproteinases 2 and 9 in human atherosclerotic and non-atherosclerotic cerebral aneurysms. Eur J Neurol 13: 1098-1105.
37. Xiang J, Natarajan SK, Tremmel M, Ma D, Mocco J, et al. (2011) Hemodynamic-morphologic discriminants for intracranial aneurysm rupture. Stroke 42: 144-152.
38. Krischek B, Tatagiba M, (2008) The influence of genetics on intracranial aneurysm formation and rupture: current knowledge and its possible impact on future treatment. Adv Tech Stand Neurosurg 33: 131-147.
39. Kassam AB, Horowitz M, Chang YF, Peters D, (2004) Altered arterial homeostasis and cerebral aneurysms: a molecular epidemiology study. Neurosurgery 54: 1460-1462.
40. Rahme RJ, Batjer HH, Bendok BR, (2010) Multiplicative impact of smoking and genetic predisposition on intracranial aneuysm formation. Neursurgery 67: 15-16.
41. Biros E, Golledge J, (2008) Meta-analysis of whole-genome linkage scans for intracranial anaeurysm. Neurosci Lett 431: 31-35.
42. Xu HW, Yu SQ, Mei CL, Li MH, (2011) Screening for intracranial aneurysm in 355patients with autosomal-dominant polycystic kidney disease. Stroke 42: 204-206.
43. Wang W, Mei C, Tang B, Zhao H, Xu C, et al. (2006) Aberrant expression of SPARC and its impact on proliferation and apoptosis in ADPKD cyst-lining epithelia. Nephrol Dial Transplant 21: 1278-1288.
44. Peters DG, Kassam AB, Feingold E, Heidrich-O'Hare E, Yonas H, et al. (2001) Molecular anatomy of an intracranal aneurysm: coordinated expression of genes involved in wound healing and tissue remodeling. Stroke 32: 1036-1042.
45. Pichler RH, Hugo C, Shankland SJ, Reed MJ, Bassuk JA, et al. (1996) SPARC is expressed in renal inrerstitial fibrosisi and in renal vascular injury. Kindney Int 50: 1978-1989.
46. Hohenester E, Sasaki T, Giudici C, Farndale RW, Bächinger HP, (2008) Structural basis of sequence-specific collagen recognition by SPARC. Proc Natl Acad Sci USA 105: 18273-18277.
47. Capper D, Mittelbronn M, Goeppert B, Meyermann R, Schittenhelm J, (2010) Secreted protein, acidic and rich in cysteine (SPARC) expression in astrocytic tumor cells negatively correlates with proliferation, while vascular SPARC ecpression is associated with patient survival. Neuropathol Appl Neurobiol 36: 183-197.
48. Bradshaw AD, (2009) The role of SPARC in extracellular matrix assembly. J Cell Commun Signal 3: 239-246.
49. Seet LF, Su R, Toh LZ, Wong TT, (2012) In vitro analyses of the anti-fibrotic effect of SPARC silencing in human Tenon's fibroblasts: comparisons with mitomycin-C. J Cell Mol Med 16: 1245-1259.
50. Jin D, Sheng J, Yang X, Gao B, (2007) Matrix metalloproteinases and tissue inhibitors of metalloproteinases expression in human cerebral ruptured and unruptured aneurysm. Surg Neurol 2: 11-16.
51. Seet LF, Su R, Barathi VA, Lee WS, Poh R, et al. (2010) SPARC deficiency results in improved surgical survival in a novel mouse model of glaucoma filtration surgery. PLoS One 5: 9415.
52. Raines EW, Lane TF, Iruela-Arispe ML, Ross R, Sage EH, (1992) The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci U S A 89: 1281-1285.
53. Kupprion C, Motamed K, Sage EH, (1998) SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem 273: 29635-29640.
54. Motamed K, Blake DJ, Angello JC, Allen BL, Rapraeger AC, et al. (2003) Fibroblast growth factor receptor-1 mediates the inhibition of endothelial cell proliferation and the promotion of skeletal myoblast differentiation by SPARC: a role for protein kinase A. J Cell Biochem. 90: 408-423.
55. McCurdy S, Baicu CF, Heymans S, Bradshaw AD, (2010) Cardiac extracellular matrix remodeling: fibrillar collagens and Secreted Protein Acidic and Rich in Cysteine (SPARC). J Mol Cell Cardiol 48: 544-549.
56. Iwamoto H, Kiyohara Y, Fujishima M, Kato I, Nakayama K, et al. (1999) Prevalence of intracranial saccular aneurysms in a Japanese community based on a consecutive autopsy series during a 30-year observation period. The Hisayama study. Stroke 30: 1390-1395.
57. Nahed BV, DiLuna ML, Morgan T, Ocal E, Hawkins AA, et al. (2005) Hypertension, age, and location predict rupture of small intracranial aneurysms. Neurosurgery 57: 676-683.
58. Taylor CL, Yuan Z, Selman WR, Ratcheson RA, Rimm AA, (1995) Cerebral arterial aneurysm formation and rupture in 20,767 elderly patients: hypertension and other risk factors. J Neurosurg 83: 812-819.
59. Ribourtout E, Raymond J, (2004) Gene therapy and endovascular treatment of intracranial aneurysms. Stroke 35(3): 786-793.